You are here:

Cilostazol (Pletal®)

Advice

Following a resubmission

Cilostazol (Pletal) is not recommended for use within NHS Scotland for improvement of the maximal and pain-free walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis.

Although in clinical trials, cilostazol improved pain-free and maximal-walking distances and had limited effects on quality of life assessments of physical function and pain, its efficacy and safety profile in Scottish patients, who are concomitantly treated with an antiplatelet drug, is unclear. The clinical effectiveness and cost-effectiveness were not demonstrated.

Drug Details

Drug Name: Cilostazol (Pletal®)
SMC Drug ID: 86/04
Manufacturer: Otsuka Pharmaceutical Europe
Indication: Maximal and pain-free walking distances in patients with intermittent claudication
BNF Category:
Submission Type: Resubmission
Status: Superseded
Date Advice Published: 7 November 2005

Archived Advice

Full submission 9 February 2004

Back